Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis.
Saberi S, Cardim N, Yamani M, Schulz-Menger J, Li W, Florea V, Sehnert AJ, Kwong RY, Jerosch-Herold M, Masri A, Owens A, Lakdawala NK, Kramer CM, Sherrid M, Seidler T, Wang A, Sedaghat-Hamedani F, Meder B, Havakuk O, Jacoby D. Saberi S, et al. Among authors: cardim n. Circulation. 2021 Feb 9;143(6):606-608. doi: 10.1161/CIRCULATIONAHA.120.052359. Epub 2020 Nov 15. Circulation. 2021. PMID: 33190524 No abstract available.
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D; EXPLORER-HCM study investigators. Olivotto I, et al. Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29. Lancet. 2020. PMID: 32871100 Clinical Trial.
EACVI survey on hypertrophic cardiomyopathy.
Podlesnikar T, Cardim N, Ajmone Marsan N, D'Andrea A, Cameli M, Popescu BA, Schulz-Menger J, Stankovic I, Toplisek J, Maurer G, Haugaa KH, Dweck MR. Podlesnikar T, et al. Among authors: cardim n. Eur Heart J Cardiovasc Imaging. 2022 Apr 18;23(5):590-597. doi: 10.1093/ehjci/jeab270. Eur Heart J Cardiovasc Imaging. 2022. PMID: 34957501
Complete recovery of myocardial inflammation imaged by T2 mapping.
Costa C, Ferreira AM, Morais Sarmento P, Cardim N, Marques H. Costa C, et al. Among authors: cardim n. Rev Port Cardiol. 2016 Sep;35(9):503-4. doi: 10.1016/j.repc.2015.11.030. Epub 2016 Aug 3. Rev Port Cardiol. 2016. PMID: 27498235 Free article. English, Portuguese. No abstract available.
The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results.
Cardim N, Brito D, Rocha Lopes L, Freitas A, Araújo C, Belo A, Gonçalves L, Mimoso J, Olivotto I, Elliott P, Madeira H; participating centres. Cardim N, et al. Rev Port Cardiol (Engl Ed). 2018 Jan;37(1):1-10. doi: 10.1016/j.repc.2017.08.005. Epub 2018 Jan 19. Rev Port Cardiol (Engl Ed). 2018. PMID: 29358015 Free article. English, Portuguese.
The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
Freitas P, Ferreira AM, Arteaga-Fernández E, de Oliveira Antunes M, Mesquita J, Abecasis J, Marques H, Saraiva C, Matos DN, Rodrigues R, Cardim N, Mady C, Rochitte CE. Freitas P, et al. Among authors: cardim n. J Cardiovasc Magn Reson. 2019 Aug 15;21(1):50. doi: 10.1186/s12968-019-0561-4. J Cardiovasc Magn Reson. 2019. PMID: 31412875 Free PMC article.
190 results